Healios KK Ord Shs HLOSF

Healthcare Biotechnology

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.

PINL:HLOSF - Post by User

Healios KK Ord Shs > REh RE: F.C.C.C Report Halo(Nov 8th)-Target 2.10

<< Previous

Bullboard Posts

Next >>

Comment by Camaronion Nov 09, 2010 9:08am

120 Views

Post# 17679114

REh RE: F.C.C.C Report Halo(Nov 8th)-Target 2.10

This was written by the same analyst in Sept 2010. Before FCC was hired for PR by HALO.

Halo Resources Ltd. (HLO-TSXV)

Michael G. Fowler, M.Sc, MBA
Halo Announces Significant Geophysical Anomalies On Lost Lake Extension – Positive: The company announced that as a result of a deep penetrating geophysical technique that the Lost Lake copper-zinc metal deposit lookalikes may occur on the strike extension and within 1,000 metres. The deep penetrating electromagnetic method can detect base metal deposits below 200 metres in depth, a level at which there has been no drilling in the past. Although this is positive, the proof will be in the pudding, in that these anomalies will have to be drill tested. We continue to rate the shares a speculative buy with a $2.10 target.